Innoviva Inc (INVA) Stock Analysis

Innoviva Inc (INVA) is a publicly traded company in the HEALTHCARE sector. It trades at $21.35, carries a market capitalization of $1.59B, a price-to-earnings ratio of 3.44. This page summarizes the public market data, fundamentals, and frequently asked questions for INVA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Innoviva Inc currently has a Bullish sentiment score of 0.36.

About Innoviva Inc

Innoviva, Inc. is a biopharmaceutical company headquartered in Burlingame, California, specializing in the development and commercialization of innovative therapies targeting respiratory diseases. The company leverages proprietary technologies and strategic collaborations with leading healthcare partners to create advanced treatment solutions that significantly enhance patient outcomes. With a diverse and robust pipeline, Innoviva is dedicated to addressing pressing unmet medical needs and ad...

GNG Research Analysis

GNG Research scores Innoviva Inc (INVA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INVA.

Frequently Asked Questions

Does INVA pay dividends?

Innoviva Inc (INVA) does not currently pay a regular dividend.

What is INVA's P/E ratio?

Innoviva Inc has a price-to-earnings (P/E) ratio of 3.44.

What is INVA's market cap?

Innoviva Inc (INVA) has a market capitalization of $1.59B with a current stock price of $21.35.